Mounjaro (tirzepatide (T2D injection)): the 2026 GLP-1 guide

Overview

Mounjaro is Eli Lilly’s tirzepatide subcutaneous injection, FDA-approved on May 13, 2022 for the treatment of type 2 diabetes. It is the same molecule as Zepbound but with a T2D-only label — they are not interchangeable for insurance purposes.

Tirzepatide is a dual GIP / GLP-1 receptor agonist. The dual mechanism produces both robust glycemic control and meaningful weight loss as a secondary effect, even though weight management is not Mounjaro’s on-label indication.

Clinical Efficacy

In SURPASS-2 (1,879 adults with T2D inadequately controlled on metformin), Mounjaro at 15 mg produced 2.30% A1c reduction and 11.2% body-weight loss at 40 weeks vs 1.86% A1c and 5.7% loss with semaglutide 1 mg¹. Across the SURPASS program, Mounjaro consistently demonstrated greater A1c reduction and weight loss than active comparators including insulin glargine and semaglutide.

For diabetes patients, Mounjaro is among the most effective non-insulin agents available in 2026 — both for glycemic control (A1c -1.7% to -2.4% range) and for weight reduction (8–13% range).

Dosing & Titration

Six approved dose strengths, identical to Zepbound:

• 2.5 mg — starting dose, 4 weeks only (titration step)
• 5 mg — first therapeutic dose
• 7.5 mg — escalation step
• 10 mg — common maintenance dose
• 12.5 mg — escalation step
• 15 mg — maximum approved dose

Schedule: start at 2.5 mg once weekly for 4 weeks. Increase to 5 mg, then in 2.5 mg increments every 4+ weeks as needed for additional glycemic control. If a dose is missed, administer within 4 days; if more than 4 days have passed, skip and resume the regular weekly schedule².

For pediatric patients (≥10 years), maximum is 10 mg weekly.

Side Effects

Boxed warning — Risk of Thyroid C-Cell Tumors

Tirzepatide causes thyroid C-cell tumors in rats at clinically relevant exposures; human relevance is unknown. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)².

Most common adverse reactions (Mounjaro 15 mg vs placebo)

GI events are dose-dependent and typically peak during the first 12 weeks of titration.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to tirzepatide or excipients

2026 Availability

Mounjaro is on Part D Tier 4 with most plans (92 indexed). Cash list price is approximately $1,069/month.

Mounjaro is NOT on the Medicare GLP-1 Bridge program — Bridge eligibility is restricted to medications with an on-label chronic-weight-management indication. For weight-loss patients, the on-label tirzepatide product is Zepbound (KwikPen formulation Bridge-covered at $50/month).

Patients with T2D who also want weight reduction generally find their insurance covers Mounjaro under their diabetes benefit — and the weight-loss effect comes as a secondary benefit alongside glycemic control. Patients without T2D should pursue Zepbound rather than off-label Mounjaro: insurance will not cover off-label use, and the Medicare Bridge does not apply.